Vericel Corporation: FY2016 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016; filed March 13, 2017. The filing also provides unaudited fourth-quarter results. Vericel is a U.S.-focused commercial-stage cell-therapy company with Carticel, Epicel and newly approved MACI, plus development-stage ixmyelocel-T.
Business context and key developments
- FDA approved MACI on December 13, 2016; the first shipment and implantation occurred January 31, 2017.
- MACI is intended to replace Carticel, with Carticel manufacturing and marketing expected to end as soon as practicable, potentially by the end of the second quarter of 2017.
- Epicel received revised labeling for pediatric patients in February 2016 and became eligible to be sold for profit, subject to an annual distribution number of 360,400 devices.
- Ixmyelocel-T’s Phase 2b ixCELL-DCM study met its primary endpoint of reducing clinical cardiac events, with comparable adverse-event incidence versus placebo. Vericel had no current plan to fund a Phase 3 trial independently and was evaluating strategic partners and other financing sources.
Financial results and metrics
| ($ millions, except per-share data) | FY2016 | FY2015 | Change |
|---|---|---|---|
| Net product revenue | 54.4 | 51.2 | +6.3% |
| Gross profit | 26.1 | 24.7 | +5.6% |
| Gross margin | 47.9% | 48.3% | -0.4 pts |
| Operating loss | (19.2) | (16.7) | Worsened by 2.6 |
| Net loss | (19.6) | (16.3) | Worsened by 3.2 |
| Net loss per share | $(1.18) | $(0.97) | Worsened by $0.21 |
| Cash used in operations | (19.9) | (13.3) | Higher use of 6.5 |
- Carticel revenue was $38.9 million, up from $35.2 million; Epicel revenue was $15.5 million, up from $15.2 million. MACI generated no material 2016 revenue.
- Fourth-quarter 2016 revenue was $16.5 million, gross profit was $8.9 million, operating loss was $5.9 million and net loss was $6.2 million, or $0.34 per share. Fourth-quarter revenue increased from $15.4 million in the comparable 2015 quarter.
- Research and development expense declined to $15.3 million from $18.9 million, primarily because of lower MACI regulatory and development costs and lower ixCELL-DCM costs.
- Selling, general and administrative expense increased to $27.4 million from $22.5 million, reflecting reimbursement and patient-support infrastructure, facility and technology costs, personnel, MACI launch preparation and higher bad-debt expense.
- Vericel recorded a $2.6 million impairment charge for commercial-use rights, primarily related to Carticel, following MACI approval and the planned product transition.
Liquidity, debt and capital resources
- Cash was $23.0 million at December 31, 2016, compared with $14.6 million at December 31, 2015. Working capital was $31.9 million, compared with $15.2 million.
- Accounts receivable increased to $17.1 million from $10.9 million, largely because Vericel assumed greater collection risk after moving to a direct Carticel sales model on July 1, 2016.
- Outstanding debt included $8.0 million of term loans and $2.5 million drawn under a revolving facility. Revolving availability was $7.5 million; the facility also included an undrawn $2.0 million term-loan tranche available following MACI approval.
- The debt facility bears interest at specified premiums over Wall Street Journal Prime, matures in 2020, is secured by substantially all assets other than intellectual property and includes minimum-revenue covenants and subjective material-adverse-change provisions.
- Vericel raised approximately $18.0 million net in a December 2016 equity offering and had approximately $24.2 million of remaining capacity under its $25.0 million at-the-market program at year-end.
- Management stated that cash on hand and the SVB-MidCap facility were expected to support current operations through at least March 31, 2018, but additional capital could be required if results differ from projections, debt covenants are not met or strategic development opportunities are pursued.
Material changes, outlook and risks
- The principal strategic change is the transition from Carticel to MACI. Commercial success depends on launch execution, manufacturing scale, physician adoption and securing reimbursement comparable to Carticel.
- The shift to direct sales transferred payer credit and collection risk to Vericel and contributed to higher accounts receivable and bad-debt expense.
- Revenue remains seasonal: Carticel is generally stronger in the second and fourth quarters, while Epicel is highly volatile because it serves fewer than 100 patients annually.
- The Cambridge facility is Vericel’s sole U.S. commercial manufacturing site. FDA inspections in 2016 resulted in Form 483 observations; Vericel reported completed or planned remediation and subsequently received MACI approval.
- MACI approval includes post-marketing commitments, including a U.S. pediatric clinical study. Failure to satisfy commitments could place approval at risk.
- Key risks include continuing losses, dependence on future financing, debt-covenant compliance, reimbursement uncertainty, manufacturing and supplier concentration, regulatory compliance, clinical-development uncertainty for ixmyelocel-T, competition and intellectual-property expiration.
- The filing reports no material legal proceedings and no material off-balance-sheet arrangements. Management and the auditor concluded that internal control over financial reporting was effective at December 31, 2016, and the prior-year material weakness was remediated.
Important facts for investors to verify
- Actual 2017 MACI launch revenue, physician adoption, manufacturing costs and payer reimbursement.
- Whether Carticel was fully discontinued as planned and whether the transition caused revenue disruption.
- Compliance with the $52 million December 31, 2016 and $60 million December 31, 2017 minimum-revenue covenants, and availability under the debt facility.
- Cash burn, accounts-receivable collections and the timing or need for additional equity or strategic financing.
- Progress and funding arrangements for any Phase 3 ixmyelocel-T program.
- Completion of MACI post-marketing commitments, pediatric studies and ongoing FDA manufacturing requirements.
- Impact of expiring MACI-related patents, single-site manufacturing dependence and sole-source suppliers, including the Matricel membrane supply.